

RESEARCH ARTICLE

Open Access

Increased frequency of CCR4⁺ and CCR6⁺ memory T-cells including CCR7⁺CD45RA^{med} very early memory cells in granulomatosis with polyangiitis (Wegener's)

Ursula Fagin, Silke Pitann, Wolfgang L Gross and Peter Lamprecht*

Abstract

Introduction: Chemokine receptors play an important role in mediating the recruitment of T cells to inflammatory sites. Previously, small proportions of circulating Th1-type CCR5⁺ and Th2-type CCR3⁺ cells have been shown in granulomatosis with polyangiitis (GPA). Wondering to what extent CCR4 and CCR6 expression could also be implicated in T cell recruitment to inflamed sites in GPA, we investigated the expression of CCR4 and CCR6 on T cells and its association with T cell diversity and polarization.

Methods: Multicolor flow cytometry was used to analyze CCR4, CCR6, and intracellular cytokine expression of T cells from whole blood of GPA-patients ($n = 26$) and healthy controls ($n = 20$). CCR7 and CD45RA were included for phenotypic characterization.

Results: We found a significant increase in the percentages of circulating CCR4⁺ and CCR6⁺ cells within the total CD4⁺ + T cell population in GPA. In contrast, there was no difference in the percentages of CD8⁺CCR4⁺ and CD8⁺CCR6⁺ T cells between GPA and healthy controls. CCR4 and CCR6 expression was largely confined to central (T_{CM}) and effector memory T cells (T_{EM}, T_{EMRA}). A significant increase in the frequency of CCR4⁺ and CCR6⁺ T_{EMRA} and CCR6⁺ T_{CM} was shown in GPA. Of note, we could dissect CCR4 and CCR6 expressing CCR7⁺CD45RA^{med} very early memory T cells (T_{VEM}) from genuine CCR7⁺CD45RA^{high} naïve T cells lacking CCR4 and CCR6 expression for peripheral tissue-migration within the CCR7⁺CD45RA⁺ compartment. The frequencies of CCR4⁺ and CCR6⁺ T_{VEM} were also significantly increased in GPA. An increased percentage of IL-17⁺ and IL-22⁺ cells was detected in the CCR6⁺ cell subsets and IL-4⁺ cells in the CCR4⁺ cell subset when compared with CD4⁺ cells lacking CCR4 and CCR6 expression.

Conclusions: Increased frequencies of circulating CCR4⁺ and CCR6⁺ memory T cell subsets including hitherto unreported T_{VEM} suggest persistent T cell activation with the accumulation of CCR4⁺ and CCR6⁺ cells in GPA. CCR4 and CCR6 could be involved in the recruitment of T cells including cytokine-producing subsets to inflamed sites in GPA.

Introduction

T cells display considerable heterogeneity in terms of phenotype, function, and anatomical distribution. Whereas naïve T cells represent a relatively homogeneous population, primed T cells acquire effector functions and differentiate into distinct effector and memory

subsets. Whereas naïve and central memory T cells home to secondary lymphoid organs to mount antigen-driven proliferative responses, effector memory T cells migrate into peripheral tissues to display immediate effector functions such as cytokine production or cytotoxicity or both [1,2]. The process of T cell recruitment from blood into tissue is controlled by adhesion molecules, in which chemokine receptors have an important role [2].

* Correspondence: peter.lamprecht@uk-sh.de
Department of Rheumatology, Vasculitis Center UKSH and Clinical Center
Bad Bramstedt, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck,
Germany

Previously, we showed that a small proportion of circulating memory T cells displays T-helper cell 1 (Th1)-type CC chemokine receptor (CCR) 5 and Th2-type CCR3 expression in granulomatosis with polyangiitis (GPA) [3]. GPA is a rare chronic inflammatory disorder of unknown etiology and is characterized by necrotizing granulomatosis of the upper or lower respiratory tract or both and a systemic autoimmune vasculitis preferentially affecting pulmonary and renal small vessels. The vasculitis is associated with highly specific anti-neutrophil cytoplasmic autoantibodies to proteinase 3 (PR3-ANCA) [4]. T cells are abundant in inflammatory lesions in GPA. CCR5, CCR3, and their chemokine ligand CCL5 (regulated upon activation in normal T cells, expressed and secreted, or RANTES) are expressed in granulomatous lesions of the respiratory tract. These studies suggested that CCR5 and CCR3 could be involved in the recruitment of interferon-gamma (IFN γ)-producing and tumor necrosis factor-alpha-producing Th1- and interleukin (IL)-4-producing Th2-type cells to inflammatory sites in GPA [5-7]. More recently, IL-17-producing PR3-specific Th17 cells have been implicated in the maintenance of chronic inflammation and autoimmunity in GPA [8-10]. CCR4⁺ T cells have been reported to secrete IL-4, whereas CCR6⁺ cells produce IL-17 [11,12]. To investigate the extent to which the chemokine receptors CCR4 and CCR6 could be implicated in T-cell recruitment in GPA, we analyzed CCR4 and CCR6 expression on circulating T cells, assigned CCR4- and CCR6-expressing cells to the respective memory cell subsets, and determined the cytokine production of CCR4⁺ and CCR6⁺ T cells.

Materials and methods

Study population

Patients fulfilled the American College of Rheumatology criteria and the Chapel Hill Consensus Conference definition for GPA, respectively [13,14]. Disease activity was recorded in accordance with European League Against Rheumatism recommendations (Table 1) [15]. All patients and controls provided informed consent. The study was approved by the local ethics committee (#07-059).

Antibodies used for flow cytometry

The following antibodies were used in different combinations: Pacific blue (PB)-conjugated anti-CD3, PB- or phycoerythrin (PE)-conjugated anti-CD4, peridinin chlorophyll protein (PerCP)- or allophycocyanine-cyanine dye 7 (APC-Cy7)-conjugated anti-CD8, fluorescein isothiocyanate (FITC)-conjugated anti-CD45RA, Alexa Fluor 647-conjugated anti-CCR7, PE-Cy7- and PE-conjugated anti-CCR4, PE-conjugated anti-CCR6, APC-Cy7-conjugated anti-IFN γ , PE-Cy7-conjugated anti-IL-4, and Alexa Fluor 488-conjugated anti-IL-17a from

eBioscience (Frankfurt, Germany) and APC-conjugated anti-IL-22 from R&D Systems (Wiesbaden, Germany). Appropriate isotype controls were included in the experimental setup. All antibodies (unless indicated otherwise) were purchased from BD Biosciences (Heidelberg, Germany).

Surface marker and intracellular cytokine staining

Flow cytometry was performed to characterize T cell populations at the single-cell level. Staining of cellular surface markers was performed by using freshly collected whole blood (Li-heparin) as described earlier [3]. Briefly, previously determined optimal concentrations of fluorochrome-conjugated monoclonal antibodies for cell surface antigens were added to 100 μ L of whole blood and incubated 45 minutes in the dark at 4°C. Subsequently, erythrocytes were lysed by the addition of FACS (fluorescence-activated cell sorting) Lysing Solution (BD Pharmingen, Heidelberg, Germany). After incubation for another 10 minutes in the dark at room temperature, cells were washed twice with phosphate-buffered saline/0.01% bovine serum albumin and immediately analyzed by FACS.

For intracellular cytokine staining, freshly collected whole blood was stimulated with phorbol myristate acetate (Sigma, Munich, Germany) (10 ng/mL) and ionomycin (Sigma) (1 μ g/mL) for 4 hours at 37°C in a humidified atmosphere with 5% CO₂. Brefeldin (Sigma) (10 μ g/mL) was added at the beginning of the stimulation to inhibit cytokine secretion. After staining for surface antigens and lysing of erythrocytes with FACS Lysing Solution, cells were fixed and permeabilized with Cytofix/Cytoperm in accordance with the instructions of the manufacturer (BD Pharmingen). Staining of intracytoplasmatic cytokines was performed at 4°C for 45 minutes in the dark with previously determined optimal concentrations of fluorochrome-conjugated monoclonal antibodies for cytokines or appropriate negative (isotype) controls. Besides appropriate isotype controls, an unstimulated sample was included for each patient and control as a negative control.

Flow cytometric analysis

Multicolor flow cytometric analysis was performed on a FACS Canto II cytometer by using FACSDiva software (BD Biosciences). Lymphocytes were gated for analysis on the basis of light scattering properties and of CD3, CD4, and CD8 staining. Positively and negatively stained populations were calculated by quadrant dot plot analysis determined by isotype controls.

Statistical analysis

Statistics were performed by using Prism 4.0 (GraphPad Software, La Jolla, CA, USA). Comparisons between

Table 1 Clinical and laboratory characteristics of patients with GPA and healthy controls

	Patients with GPA in remission	Patients with active GPA	Healthy controls
Number	12	14	20
Age in years, mean (range)	58 (38-83)	55 (27-77)	51 (21-78)
Sex, male/female	10/2	10/4	11/9
BVAS V3.0, mean (range)	0	10 (4-21)	
CRP in mg/L, mean (range)	8 (1-17)	33 (1-86)	
PR3-ANCA, positive/negative	9/3	14/0	
Methotrexate, number	9	5	
Azathioprine, number	1	0	
Leflunomide, number	2	0	
Cyclophosphamide, number	0	5	
Prednisolone, number	12	10	
Prednisolone dosage in mg	6.1 ± 0.8	11.9 ± 1.9 ^a	
No treatment	0	4	

Remission was defined as BVAS V3.0 (Birmingham Vasculitis Activity Index version 3.0) of 0. Disease activity in patients either with first manifestation or relapsing was defined as BVAS V3.0 of at least 1 (15). Prednisolone dosage is expressed as mean ± standard error of the mean. ^a*P* < 0.05 by Mann-Whitney *U* test. CRP, C-reactive protein; GPA, granulomatosis with polyangiitis; PR3-ANCA, anti-neutrophil cytoplasmic autoantibodies targeting proteinase 3.

patients and control subjects were done by employing the non-parametric Mann-Whitney *U* test. *P* values equal to or less than 0.05 were considered to be statistically significant.

Results


Increased frequency of CCR4- and CCR6-expressing CD4⁺ T cells in granulomatosis with polyangiitis

To assess CCRs relevant for migration to peripheral tissues, we determined the expression of the CCR4 and CCR6 on peripheral blood T cells in patients with GPA and healthy controls. We found a significant increase in the percentages of CCR4- and CCR6-expressing cells within the total CD4⁺ T cell population in patients with GPA compared with healthy individuals (Figure 1a, b). Apart from the CCR4⁺CCR6⁻ and CCR4⁻CCR6⁺ 'single positive' subsets, a smaller fraction of CCR4⁺CCR6⁺ 'double positive' cells was detected within the CD4⁺ T cell population in patients with GPA and healthy controls (17.5% ± 4.8% versus 10.3% ± 0.6%, mean ± standard error of the mean, no significant difference, Mann-Whitney *U* test). Conversely, the remainder of cells within the CD4⁺ T-cell population were CCR4⁻CCR6⁻ 'double negative' cells. In contrast, there was no difference in the percentages of CD8⁺CCR4⁺ and CD8⁺CCR6⁺ T cells between patients with GPA and healthy controls (data not shown).

CCR4 and CCR6 are expressed on distinct memory cell populations, including CCR7⁺CD45RA^{med} very early memory cells

Having shown a significant increase in the frequencies of CCR4- and CCR6-expressing CD4⁺ T cells in patients with GPA, we were interested in phenotypic features of


CCR4- and CCR6-expressing CD4⁺ T cells next. To assign CCR4⁺ and CCR6⁺ cells to the respective naïve and memory cell subsets, cells were additionally stained with fluorescent-conjugated antibodies for CD45RA and CCR7 to allow discrimination into diverse T cell subsets [2,16-18]. By the use of these markers, we found that CCR4 and CCR6 expression was confined largely to the circulating CCR7⁺CD45RA⁻ central memory (T_{CM}) and CCR7⁻CD45RA⁻ (T_{EM}) and CCR7⁻CD45RA⁺ (T_{EMRA}) effector memory cell subsets within the total CD4⁺ T cell population. A significant increase in the frequency of CCR4⁺ and CCR6⁺ cells was remarkable in the CCR7⁻CD45RA⁺ effector memory (T_{EMRA}) subset in patients with GPA. A significant increase in CCR6⁺ cells was also found in the CCR7⁺CD45RA⁻ central memory T-cell subset (T_{CM}). However, significantly increased percentages of CCR4⁺ and CCR6⁺ cells were also detected in the CCR7⁺CD45RA⁺ population, which contains naïve T cells (T_N) by definition (Figure 2a, b). Dissecting the CCR7⁺CD45RA⁺ population with respect to CD45RA fluorescence intensity, we detected two subsets in the CCR7⁺CD45RA⁺ population. CCR7⁺CD45RA^{high} T cells generally lacked CCR4 and CCR6 expression with the exception of three patients with GPA. In contrast, CCR7⁺CD45RA^{med} T cells displayed CCR4 and CCR6 expression. We found higher frequencies of CCR4⁺ and CCR6⁺ cells within the CCR7⁺CD45RA^{med} T cell subset in patients with GPA compared with healthy controls (Figure 2c, d). Thus, the CCR7⁺CD45RA⁺ population contained genuine CCR7⁺CD45RA^{high} T_N lacking CCR4 and CCR6 expression and another CCR7⁺CD45RA^{med} T cell subset comprising CCR4⁺ and CCR6⁺ cells. The latter was reminiscent of so-called very early memory T cells (T_{VEM}) [19].



Decreased frequency of CCR7⁺CD45RA^{high} naïve T cells and unreduced frequency of CCR7⁺CD45RA^{med} very early memory T cells in granulomatosis with polyangiitis

Earlier studies have reported significantly lower percentages of peripheral blood T_N by using CCR7 and CD45RO or CD45RB expression for the phenotypic characterization of T cells in patients with GPA [20,21]. In this study, we showed a segregation of the CCR7

⁺CD45RA⁺ T cell compartment into different two subsets based on CCR4 and CCR6 expression and CD45RA fluorescence intensity. This prompted us to investigate whether T_N and T_{VEM} frequencies were likewise decreased within the total CD4⁺ T-cell population. In line with the aforementioned earlier studies, we found a significantly lower percentage of CCR7⁺CD45RA^{high} T_N in patients with GPA compared with healthy controls




[20,21]. In contrast, CCR7⁺CD45RA^{med} T_{VEM} frequencies were similar in patients with GPA and healthy individuals (Figure 3).

Distinct cytokine-producing subsets within CCR4⁺ and CCR6⁺ T-cell populations

We showed increased frequencies of circulating CCR4- or CCR6-expressing (or both) CD4⁺ T_{CM}, T_{EMRA}, and T_{VEM} in patients with GPA. To investigate functional features of CCR4⁺ and CCR6⁺ cells within the total CD4⁺ T cell population, peripheral blood cells were stained for intracellular cytokines. An IFN γ ⁺ cell fraction was found in all CCR4⁺ or CCR6⁺ subsets or both. An

increased percentage of IL-17⁺ and IL-22⁺ cells was detected in the CCR4⁻CCR6⁺ 'single positive' and CCR4⁺CCR6⁺ 'double positive' cell fractions when compared with the CCR4⁻CCR6⁻ 'double negative' cell subset. Furthermore, an increased frequency of IL-4⁺ cells was shown in the CCR4⁺CCR6⁻ 'single positive' cell fraction compared with the CCR4⁻CCR6⁻ 'double negative' cell subset in both patients with GPA and healthy controls. CCR4⁻CCR6⁺ 'single positive' and CCR4⁺CCR6⁺ 'double positive' cells differed from each other with respect to the percentage of IFN γ -producing cells, which was significantly higher in the CCR4⁻CCR6⁺ 'single positive' fraction ($P < 0.01$, Mann-Whitney U test). The CCR4⁻



$CCR6^-$ 'double negative' cell subset differed from the other subsets in that only an $IFN\gamma^+$ cell fraction was remarkable in this subset (Table 2). Less than 1% of cells displayed intracellular co-expression of IL-17 and IL-22 in $CCR6^+$ cells within the total $CD4^+$ T-cell population (data not shown). Thus, circulating $CD4^+CCR4^+$ and $CD4^+CCR6^+$ T cell populations comprised distinct subsets of cytokine-producing cells.

Discussion

Chemokine receptors play an important role in mediating T cell recruitment to distinct anatomical sites and tissues [2]. Whereas the CC chemokine receptor $CCR7$ mediates homing of naïve (T_N) and central memory (T_{CM}) T cells to lymph nodes, other CC and CXC

chemokine receptors ($CCR/CXCR$) trigger intravascular adhesion and direct migration of effector memory T cell subsets ($CD45RA^- T_{EM}$ and $CD45RA^+$ 'reverted' T_{EMRA}) into peripheral tissues for patrol and recruitment to inflammatory sites [2,19]. Previously, cloned $CCR6^+$ cells from peripheral blood and inflammatory sites in Crohn's disease have been shown to produce IL-17. In contrast, $CCR4^+$ cells secrete IL-4 [11,12,22]. Recently, Th17-, Th22-, and Th2-type PR3-specific cells have been suggested to be involved in chronic inflammation and autoimmunity in GPA [8-10,23]. Moreover, an increased proportion of circulating $CD45RC^{low}$ Th2-type and Th17 cells has been reported in ANCA-associated vasculitides, including GPA. The increase is independent of disease duration and treatment [24]. Therefore, to

Table 2 Percentages of cytokine-producing $CCR4^+$ and/or $CCR6^+$ cell subsets within the total $CD4^+$ T cell population compared with the $CCR4^-CCR6^-$ cell subset

	Granulomatosis with polyangiitis			
	$CCR4^-CCR6^-$ cells	$CCR4^+CCR6^-$ cells	$CCR4^-CCR6^+$ cells	$CCR4^+CCR6^+$ cells
Percentage of $IFN\gamma^+$ cells	11.3 \pm 5.1	5.5 \pm 2.0	28.2 \pm 4.3	4.0 \pm 0.5
Percentage of IL-4 ⁺ cells	1.0 \pm 0.5	5.5 \pm 1.5 ^a	0.6 \pm 0.3	1.0 \pm 0.4
Percentage of IL-17 ⁺ cells	0.1 \pm 0.0	0.1 \pm 0.0	7.8 \pm 1.8 ^a	9.5 \pm 0.9 ^b
Percentage of IL-22 ⁺ cells	0.1 \pm 0.0	0.2 \pm 0.1	2.4 \pm 0.5 ^a	3.4 \pm 0.6 ^a
	Healthy controls			
	$CCR4^-CCR6^-$ cells	$CCR4^+CCR6^-$ cells	$CCR4^-CCR6^+$ cells	$CCR4^+CCR6^+$ cells
Percentage of $IFN\gamma^+$ cells	21.7 \pm 8.4	13.1 \pm 2.0	30.7 \pm 1.1	6.0 \pm 0.5
Percentage of IL-4 ⁺ cells	1.0 \pm 0.3	5.4 \pm 1.0 ^a	1.5 \pm 0.4	2.2 \pm 0.6
Percentage of IL-17 ⁺ cells	0.1 \pm 0.0	0.2 \pm 0.0	9.1 \pm 1.0 ^a	9.7 \pm 1.8 ^a
Percentage of IL-22 ⁺ cells	0.1 \pm 0.0	0.4 \pm 0.2	3.3 \pm 0.9 ^a	5.0 \pm 2.1 ^a

Percentages of positive cells were assessed by flow cytometry. Values are expressed as mean \pm standard error of the mean. ^a $P < 0.5$, ^b $P < 0.01$, Mann-Whitney U test. CCR, CC chemokine receptor; $IFN\gamma$, interferon-gamma; IL, interleukin.

investigate the extent to which CCR4 and CCR6 expression could be implicated in T-cell recruitment in GPA, we analyzed the expression of these chemokine receptors on T cells.

In this study, we found increased frequencies of circulating CCR4⁺ and CCR6⁺ cells within the total CD4⁺ T cell population in GPA. In contrast, we found no significant increase in the frequencies of CCR4⁺ and CCR6⁺ cells in the total CD8⁺ T cell population. CCR4 and CCR6 expression suggests T cell activation [11,12]. Persistent T cell activation regardless of clinical disease activity has been reported in GPA [20,21,25]. Recently, stable CCR6 expression was reported to be controlled by epigenetic mechanisms [26]. In line with previous reports, CCR4 and CCR6 expression was confined largely to circulating CCR7⁺CD45RA⁻ central memory (T_{CM}), CCR7⁻CD45RA⁻ (T_{EM}), and CCR7⁻CD45RA⁺ (T_{EMRA}) effector memory CD4⁺ T cells [11,12]. We found a significant increase in the frequency of CCR4⁺ and CCR6⁺ T_{EMRA} and CCR6⁺ T_{CM} in patients with GPA. Surprisingly, CCR4⁺ and CCR6⁺ cells were also detected within the CCR7⁺CD45RA⁺ population, which contains the naïve T cell subset (T_N) by definition. T_N are CD45RA⁺ and express CCR7 for peripheral lymph node homing but lack receptors such as CCR4 and CCR6 for the migration to peripheral tissues [2,16-18]. Further analysis dissecting the CCR7⁺CD45RA⁺ population with regard to CD45RA fluorescence intensity disclosed that the CCR7⁺CD45RA⁺ T-cell compartment contained two subsets. One subset of CCR7⁺CD45RA^{high} T cells generally lacked CCR4 and CCR6 expression with the exception of three patients with GPA. Thus, CCR7⁺CD45RA^{high} T cells represented genuine T_N. CCR4 and CCR6 expression on CCR7⁺CD45RA^{high} T_N in individual patients with GPA could represent T_N activation, which has been reported before by demonstrating an increased frequency of CD4⁺CD45RO⁻FoxP3⁻ T_N expressing the activation marker CD25 [20,25]. In line with earlier studies, we showed that the percentage of CCR7⁺CD45RA^{high} T_N within the total CD4⁺ T cell population was significantly lower in patients with GPA [20,21]. In contrast, the percentage of CCR7⁺CD45RA^{med} T cells was not decreased in patients with GPA. CCR7⁺CD45RA^{med} T cells displayed CCR4 and CCR6 expression reminiscent of so-called very early memory T cells (T_{VEM}). Higher frequencies of CCR4⁺ and CCR6⁺ cells within the CCR7⁺CD45RA^{med} T_{VEM} subset were found in patients with GPA compared with healthy controls. T_{VEM} have been described earlier as 'apparently T_N' oddly displaying chemokine receptors for both lymph node homing (CCR7) and peripheral tissue migration (CCR4 and CXCR3) in healthy individuals by Song and colleagues [19]. Analysis of the proliferation history, T-cell receptor repertoire, and cytokine

response of CCR4⁻ and CXCR3-expressing CCR7⁺CD45RO⁻ T cells suggests that these cells represent T_{VEM}, which have proceeded only a short way along the differentiation pathway from T_N to T_{CM} or T_{EM}. T_{VEM} are still multifunctional but finally differentiate into either T_{CM} or T_{EM} [19].

Earlier studies showed that chemokine receptor expression for lymph node homing (CCR7) and peripheral tissue migration (for example, CCR4) is not mutually exclusive on T cell subsets [27]. The migratory behavior of T_{EM} displaying dual-chemokine receptor expression is determined by chemotactic gradients and cytokine- and T-cell receptor (TCR)-mediated signals [28]. CCR4-expressing CCR7⁺ T_{EM} have been reported in inflamed peripheral tissues (for example, in psoriasis and juvenile idiopathic arthritis) [29,30]. Whereas CCR7⁻ T_{EM} remain in the peripheral tissue, CCR7⁺ T_{EM} migrate to peripheral tissues and subsequently exit the tissue to enter draining lymph nodes in different animal models [31,32]. Although CCR7⁺ T_{EM} retain a capability to enter lymph nodes, inflammatory cytokines can subvert migration of CCR7⁺ T_{EM}, resulting in the retention of CCR7⁺ T_{EM} in the inflamed synovial tissue [33]. Cytokines also drive the differentiation of CCR4-expressing CCR7⁺ T_{CM} to CCR7⁻ T_{EM} [22]. Of note, CCR7⁺ T_{EM} accumulate in areas of ectopic lymphoid tissue in the inflamed synovial tissue [30]. In contrast, CCR4-expressing CCR7⁺ T_{VEM} reside or recirculate in secondary lymphoid tissues, where they continue to differentiate and acquire further chemokine receptors for peripheral tissue migration [19].

Having shown increased frequencies of circulating CCR4⁻ and CCR6-expressing CD4⁺ memory T cell subsets, including T_{VEM} in patients with GPA, we analyzed the cytokine production of CCR4⁺ and CCR6⁺ T cells. Previously, cloned and, as such, preselected CCR6⁺ cells were reported to secrete IL-17, whereas CCR4⁺ T cells produce IL-4 [11,12]. In our study, we found an increased percentage of IL-17- and IL-22-producing cells in the CCR4⁻CCR6⁺ 'single positive' and CCR4⁺CCR6⁺ 'double positive' cell subsets and an increased frequency of IL-4⁺ cells in the CCR4⁺CCR6⁻ 'single positive' cell subset compared with the CCR4⁻CCR6⁻ 'double negative' cell subset within the total circulating CD4⁺ T-cell population. Thus, in line with earlier studies, we found Th17 cells within circulating CCR6⁺ cells and Th2-type cells among CCR4⁺ cells [11,12]. Moreover, CCR4⁻CCR6⁺ 'single positive' and CCR4⁺CCR6⁺ 'double positive' cells differed from each other with respect to the percentage of IFN γ -producing cells, which was higher in the former cell population.

Conclusions

We found increased frequencies of circulating CCR4⁺ and CCR6⁺ T cells in patients with GPA. CCR4 and

CCR6 expression was confined largely to central memory (T_{CM}) and effector memory (T_{EM} and T_{EMRA}) subsets but could also be detected on very early memory T cells (T_{VEM}) displaying chemokine receptors for both lymph node homing (CCR7) and peripheral tissue migration (CCR4 and CCR6). $CD4^+CCR4^+$ and $CD4^+CCR6^+$ T-cell populations contained distinct cytokine-producing subsets. Our data suggest that CCR4 and CCR6 could be involved in the recruitment of different T cell subsets, including cytokine-producing cells, to inflamed sites in patients with GPA. Further studies are needed to assess $CCR4^+$ and $CCR6^+$ T cell reactivity to the respective chemokine gradients and the expression of CCR4, CCR6, and their chemokine ligands in inflammatory lesions in patients with GPA in order to define new targets for therapeutic intervention.

Abbreviations

ANCA: anti-neutrophil cytoplasmic autoantibodies; APC: allophycocyanine; APC-Cy7: allophycocyanine-cyanine dye 7; CCR: CC chemokine receptor; CXCR: CXC chemokine receptor; Cy7: cyanine dye 7; FACS: fluorescence-activated cell sorting; GPA: granulomatosis with polyangiitis (Wegener's); IFN γ : interferon-gamma; IL: interleukin; PB: Pacific blue; PE: phycoerythrin; PR3: proteinase 3; T_{CM} : central memory T cells; T_{EM} : $CD45RA^+$ effector memory T cells; T_{EMRA} : $CD45RA^+$ effector memory T cells; Th: T-helper cell; T_N : naive T cells; T_{VEM} : very early memory T cells.

Acknowledgements

This work was supported by the German Research Foundation-funded Clinical Research Unit 170 'Early pathogenesis of Wegener's granulomatosis', Excellence Cluster 'Inflammation at Interfaces' (IRG-Ih), University-funded Priority Program Autoimmunity, and a grant from the Association for the Promotion of the Study and Control of Rheumatic Diseases (Bad Bramstedt, Germany).

Authors' contributions

UF participated in the design of the study, acquisition of data, interpretation of the results, and drafting of the manuscript. SP participated in the acquisition of data, interpretation of results, and drafting of the manuscript. WLG participated in the coordination of the study and assisted in the interpretation of the results. PL conceived the study, participated in its design and coordination and the interpretation of the results, and drafted of the manuscript. All authors read and approved the final manuscript.

Authors' information

UF, Ph.D., is a biologist. SP is a medical technician. WLG, M.D., is the director of the Department of Rheumatology and spokesman of the Vasculitis Center UKSH and Clinical Research Unit 170. PL, M.D., is the coordinator of Clinical Research Unit 170. All authors are at the Department of Rheumatology, Vasculitis Center UKSH and Clinical Center Bad Bramstedt, University of Lübeck (Lübeck, Germany).

Competing interests

The authors declare that they have no competing interests.

Received: 25 November 2011 Revised: 1 March 2012

Accepted: 10 April 2012 Published: 10 April 2012

References

1. Woodland DL, Dutton RW: Heterogeneity of $CD4^+$ and $CD8^+$ T cells. *Curr Opin Immunol* 2003, **15**:336-342.
2. Von Andrian U, Mackay CR: T-cell function and migration. Two sides of the same coin. *N Engl J Med* 2000, **343**:1020-1034.
3. Lamprecht P, Erdmann A, Mueller A, Csernok E, Reinhold-Keller E, Holl-Ulrich K, Feller AC, Bruehl H, Gross WL: Heterogeneity of $CD4^+$ and $CD8^+$

- memory T cells in localized and generalized Wegener's granulomatosis. *Arthritis Res Ther* 2003, **5**:R25-31.
4. Lamprecht P, Holle J, Gross WL: Update on clinical, pathophysiological and therapeutic aspects in ANCA-associated vasculitides. *Curr Drug Discov Technol* 2009, **6**:241-251.
5. Coulomb-L'Hermine A, Capron F, Zou W, Piard F, Galateau F, Laurent P, Crevon MC, Galanaud P, Emilie D: Expression of the chemokine RANTES in pulmonary Wegener's granulomatosis. *Hum Pathol* 2001, **32**:320-326.
6. Lamprecht P, Bruhl H, Erdmann A, Holl-Ulrich K, Csernok E, Seitzer U, Mack M, Feller AC, Reinhold-Keller E, Gross WL, Muller A: Differences in CCR5 expression on peripheral blood $CD4^+CD28^-$ T-cells and granulomatous lesions between localized and generalized Wegener's granulomatosis. *Clin Immunol* 2003, **108**:1-7.
7. Balding CE, Howie AJ, Drake-Lee AB, Savage CO: Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. *Clin Exp Immunol* 2001, **125**:332-339.
8. Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG: Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. *Arthritis Rheum* 2008, **58**:2196-2205.
9. Nogueira E, Hamour S, Sawant D, Henderson S, Mansfield N, Chavele KM, Pusey CD, Salama AD: Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. *Nephrol Dial Transplant* 2010, **25**:2209-2217.
10. Fagin U, Csernok E, Müller A, Pitann S, Fazio J, Krause K, Bremer P, Wipfler-Freißmuth E, Moosig F, Gross WL, Lamprecht P: Distinct proteinase 3-induced cytokine patterns in Wegener's granulomatosis, Churg-Strauss syndrome, and healthy controls. *Clin Exp Rheumatol* 2011, **29**(Suppl 64): S57-S62.
11. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S: Phenotypic and functional features of human Th17 cells. *J Exp Med* 2007, **204**:1849-1861.
12. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrassay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G: Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. *Nat Immunol* 2007, **8**:639-646.
13. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW Jr, Masi AT, McShane DJ, Mills JA, Stevens MB, Wallace SL, Zvaifler NJ: The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. *Arthritis Rheum* 1990, **33**:1101-1107.
14. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, McCluskey RT, Sinico RA, Rees AJ, van Es LA, Waldherr R, Wiik A: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum* 1994, **37**:187-192.
15. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott DGI, Witter J, Yazici H, Luqmani R, the European Vasculitis Study Group: EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. *Ann Rheum Dis* 2007, **66**:605-617.
16. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 1999, **401**:708-712.
17. Appay V, van Lier RAW, Sallusto F, Roederer M: Phenotype and Function of Human T Lymphocyte Subsets: Consensus and Issues. *Cytometry A* 2008, **73**:975-983.
18. De Rosa Herzenberg LA, Herzenberg LA, Roederer M: 11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity. *Nat Med* 2001, **7**:245-248.
19. Song K, Rabin RL, Hill BJ, De Rosa SC, Perfetto SP, Zhang HH, Foley JF, Reiner JS, Liu J, Mattapallil JJ, Douek DC, Roederer M, Farber JM: Characterization of subsets of $CD4^+$ memory T cells reveals early branched pathways of T cell differentiation in humans. *Proc Natl Acad Sci USA* 2005, **102**:7916-7921.
20. Marinaki S, Neumann I, Kälsch AI, Grimminger P, Breedijk A, Birk R, Schmitt W, Waldherr R, Yard BA, van der Woude FJ: Abnormalities of $CD4^+$ T cell subpopulations in ANCA-associated vasculitis. *Clin Exp Immunol* 2005, **140**:181-191.

21. Abdulhad WH, van der Geld YM, Stegeman CA, Kallenberg CG: **Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis.** *Kidney Int* 2006, **70**:938-947.
22. Rivino L, Messi M, Jarrossay D, Lanzavecchia A, Sallusto F, Geginat J: **Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells.** *J Exp Med* 2004, **200**:725-735.
23. Popa ER, Franssen CF, Limburg PC, Huitema MG, Kallenberg CG, Tervaert JW: **In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase.** *Arthritis Rheum* 2002, **46**:1894-1904.
24. Ordonez L, Bernard I, L'Faqihi-Olive FE, Cohen Tervaert JW, Damoiseaux J, Saoudi A: **CD45RC isoform expression identifies functionally distinct T cell subsets differentially distributed between healthy individuals and AAV patients.** *PLoS One* 2009, **4**:e5287.
25. Marinaki S, Kälsch AI, Grimminger P, Breedijk A, Birk R, Schmitt WH, Weiss C, van der Woude FJ, Yard BA: **Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis.** *Nephrol Dial Transplant* 2006, **21**:1825-1832.
26. Steinfeld S, Floess S, Engelbert D, Haeringer B, Baron U, Rivino L, Steckel B, Gruetzkau A, Olek S, Geginat J, Huehn J, Hamann A: **Epigenetic modification of the CCR6 gene is associated with stable CCR6 expression in T cells.** *Blood* 2011, **117**:2839-2846.
27. Campbell JJ, Murphy KE, Kunkel EJ, Brightling CE, Soler D, Shen Z, Boisvert J, Greenberg HB, Vierra MA, Goodman SB, Genovese MC, Wardlaw AJ, Butcher EC, Wu L: **CCR7 expression and memory T cell diversity in humans.** *J Immunol* 2001, **166**:877-884.
28. Foxman EF, Kunkel EJ, Butcher EC: **Integrating conflicting chemotactic signals. The role of memory in leukocyte navigation.** *J Cell Biol* 1999, **147**:577-588.
29. Teraki Y, Miyake A, Takebayashi R, Shiohara T: **Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris.** *Clin Exp Dermatol* 2004, **29**:658-663.
30. Gattorno M, Prigione I, Morandi F, Gregorio A, Chiesa S, Ferlito F, Favre A, Uccelli A, Gambini C, Martini A, Pistoia V: **Phenotypic and functional characterization of CCR7+ and CCR7- CD4+ memory T-cells homing to the joints in juvenile idiopathic arthritis.** *Arthritis Res Ther* 2005, **7**: R256-267.
31. Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, Hay JB, Butcher EC: **Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissue.** *Nat Immunol* 2005, **6**:889-894.
32. Bromley SK, Thomas SY, Luster AD: **Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics.** *Nat Immunol* 2005, **6**:895-901.
33. Zhang X, Nakajima T, Goronzy JJ, Weyand CM: **Tissue trafficking patterns of effector memory CD4+ T cells in rheumatoid arthritis.** *Arthritis Rheum* 2005, **52**:3839-3849.

doi:10.1186/ar3794

Cite this article as: Fagin *et al.*: Increased frequency of CCR4+ and CCR6 + memory T-cells including CCR7+CD45RA^{med} very early memory cells in granulomatosis with polyangiitis (Wegener's). *Arthritis Research & Therapy* 2012 **14**:R73.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

